Drug Trial Radar · NCT02769481
Safety and Efficacy of Bexagliflozin Compared to Glimepiride as Add-on Therapy to Metformin in Type 2 Diabetes Subjects
Last checked: Nov 20, 2026Latest source record: May 27, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
426
Actual
Start
Aug 15, 2016
Primary completion
Jun 14, 2019
Study completion Jun 14, 2019
Sponsor
- Lead sponsor
- TheracosIndustry
- Sponsor type
- Industry
- First posted
- May 11, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to investigate the effect of bexagliflozin compared to glimepiride as an add-on therapy to metformin in lowering hemoglobin A1c (HbA1c) levels in subjects with type 2 diabetes mellitus (T2DM).
Conditions
- Type 2 Diabetes Mellitus
Interventions
BexagliflozinDrug
20 mg, tablet
Placebo for BexagliflozinDrug
inactive tablet to match active comparator bexagliflozin
GlimepirideDrug
2, 4 or 6 mg, capsule
Placebo for GlimepirideDrug
inactive capsules to match active comparator glimepiride
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in HbA1c at Week 60Time frame: Baseline and Week 60
Locations
45 sites in 4 countries. Site status is shown where the registry gives one.
Research Site
Birmingham, Alabama
Research Site
Huntington Park, California
Research Site
Los Angeles, California
Research Site
San Carlos, California
Research Site
Hialeah, Florida
Research Site
Miami Lakes, Florida
Research Site
Orlando, Florida
Research Site
West Palm Beach, Florida
Research Site
Calabash, North Carolina
Research Site
Morehead City, North Carolina
Research Site
Magnolia, Texas
Research Site
Aschaffenburg, Germany
Research Site
Essen, Germany
Research Site 2
Essen, Germany
Research Site 2
Hamburg, Germany
Research Site
Hamburg, Germany
Research Site
Heidelberg, Germany
Research Site
Magdeburg, Germany
Research Site
Wangen, Germany
Research Site
Bochnia, Poland
Research Site
Bydgoszcz, Poland
Research Site
Krakow, Poland
Research Site 2
Krakow, Poland
Research Site
Lodz, Poland
Research Site 2
Lublin, Poland
Research Site
Lublin, Poland
Research Site
Olsztyn, Poland
Research Site
Poznan, Poland
Research Site
Puławy, Poland
Research Site
Staszów, Poland
Research Site
Swarzędz, Poland
Research Site
Świdnik, Poland
Research Site
Torun, Poland
Research Site
Warsaw, Poland
Research Site
Zamość, Poland
Research Site
Alicante, Spain
Research Site 2
Barcelona, Spain
Research Site
Barcelona, Spain
Research Site 2
Madrid, Spain
Research Site 3
Madrid, Spain
Showing 40 of 45 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.